Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia

Tuberculosis and Respiratory Diseases

Volumn 74, Issue 5, 2013, Pages 207-214

  Kim, Ji Hye ^a   Seo, Joo Wan ^a   Mok, Jeong Ha ^a   Kim, Mi Hyun ^a   Cho, Woo Hyun ^a   Lee, Kwangha ^a   Kim, Ki Uk ^a   Jeon, Doosoo ^a   Park, Hye Kyung ^a   Kim, Yun Seong ^a   Kim, Hyung Hoi ^b   Lee, Min Ki ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Aged; Community Acquired infections; Pneumonia; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; PROCALCITONIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELDERLY CARE; FEMALE; HOSPITAL ADMISSION; HUMAN; INJURY SEVERITY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROTEIN BLOOD LEVEL; UREMIA;

EID: 84879353986     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2013.74.5.207     Document Type: Article

References (30)

1. Korea National Statistical Office. 2011 Annual report on the cause of death statistics. Daejeon: Korea National Statistical Office; 2011.
2. Loeb M. Pneumonia in older persons. Clin Infect Dis 2003;37:1335-9. (Pubitemid 37433630)
3. Johnson JC, Jayadevappa R, Baccash PD, Taylor L. Nonspecific presentation of pneumonia in hospitalized older people: age effect or dementia? J Am Geriatr Soc 2000;48:1316-20.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. (Pubitemid 46290553)
5. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. (Pubitemid 27044625)
6. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6. (Pubitemid 26360177)
7. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
8. American College of Emergency Physicians. Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. Ann Emerg Med 2001;38:107-13.
9. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-94. (Pubitemid 46205946)
10. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68-73. (Pubitemid 30189610)
11. Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 2002;34:895-901. (Pubitemid 34229756)
12. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8. (Pubitemid 23066085)
13. Ahn S, Kim WY, Yoon JY, Sohn CH, Seo DW, Kim SH, et al. Procalcitonin in 2009 H1N1 influenza pneumonia: role in differentiating from bacterial pneumonia. Tuberc Respir Dis 2010;68:205-11.
14. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93. (Pubitemid 43955248)
15. Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-9. (Pubitemid 41507563)
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
17. Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984;167:93-7.
18. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73. (Pubitemid 351182082)
19. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin: a new indicator of the systemic response to severe infections. Infection 1997;25:329-34. (Pubitemid 27507299)
20. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10.
21. Christ-Crain M, Muller B. Procalcitonin in bacterial infections: hype, hope, more or less? Swiss Med Wkly 2005;135:451-60. (Pubitemid 41376648)
22. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17. (Pubitemid 38971491)
23. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139:1410-8.
24. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90. (Pubitemid 39625721)
25. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002;72:643-9. (Pubitemid 36277834)
26. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
27. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-602. (Pubitemid 44413058)
28. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-55.
29. Meng FS, Su L, Tang YQ, Wen Q, Liu YS, Liu ZF. Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality. Clin Biochem 2009;42:1025-31.
30. Stucker F, Herrmann F, Graf JD, Michel JP, Krause KH, Gavazzi G. Procalcitonin and infection in elderly patients. J Am Geriatr Soc 2005;53:1392-5. (Pubitemid 41602486)